These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 7939745

  • 21. Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q.
    Yin Z, Babaian RJ, Troncoso P, Strom SS, Spitz MR, Caudell JJ, Stein JD, Kagan J.
    Oncogene; 2001 Apr 26; 20(18):2273-80. PubMed ID: 11402322
    [Abstract] [Full Text] [Related]

  • 22. An uncertain role for p53 gene alterations in human prostate cancers.
    Brooks JD, Bova GS, Ewing CM, Piantadosi S, Carter BS, Robinson JC, Epstein JI, Isaacs WB.
    Cancer Res; 1996 Aug 15; 56(16):3814-22. PubMed ID: 8706029
    [Abstract] [Full Text] [Related]

  • 23. Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer.
    Lin SH, Pu YS.
    Semin Oncol; 1999 Apr 15; 26(2):227-33. PubMed ID: 10597733
    [Abstract] [Full Text] [Related]

  • 24. Frequent mutation of the E2F-4 cell cycle gene in primary human gastrointestinal tumors.
    Souza RF, Yin J, Smolinski KN, Zou TT, Wang S, Shi YQ, Rhyu MG, Cottrell J, Abraham JM, Biden K, Simms L, Leggett B, Bova GS, Frank T, Powell SM, Sugimura H, Young J, Harpaz N, Shimizu K, Matsubara N, Meltzer SJ.
    Cancer Res; 1997 Jun 15; 57(12):2350-3. PubMed ID: 9192806
    [Abstract] [Full Text] [Related]

  • 25. A widely expressed transcription factor with multiple DNA sequence specificity, CTCF, is localized at chromosome segment 16q22.1 within one of the smallest regions of overlap for common deletions in breast and prostate cancers.
    Filippova GN, Lindblom A, Meincke LJ, Klenova EM, Neiman PE, Collins SJ, Doggett NA, Lobanenkov VV.
    Genes Chromosomes Cancer; 1998 May 15; 22(1):26-36. PubMed ID: 9591631
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Methylation of multiple genes in prostate cancer and the relationship with clinicopathological features of disease.
    Singal R, Ferdinand L, Reis IM, Schlesselman JJ.
    Oncol Rep; 2004 Sep 15; 12(3):631-7. PubMed ID: 15289848
    [Abstract] [Full Text] [Related]

  • 28. HRK inactivation associated with promoter methylation and LOH in prostate cancer.
    Higuchi T, Nakamura M, Shimada K, Ishida E, Hirao K, Konishi N.
    Prostate; 2008 Jan 01; 68(1):105-13. PubMed ID: 18008329
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Unmethylated E-cadherin gene expression is significantly associated with metastatic human prostate cancer cells in bone.
    Saha B, Kaur P, Tsao-Wei D, Naritoku WY, Groshen S, Datar RH, Jones LW, Imam SA.
    Prostate; 2008 Nov 01; 68(15):1681-8. PubMed ID: 18712716
    [Abstract] [Full Text] [Related]

  • 31. Methylation of tumor suppressor genes p16(INK4a), p27(Kip1) and E-cadherin in carcinogenesis.
    Auerkari EI.
    Oral Oncol; 2006 Jan 01; 42(1):5-13. PubMed ID: 15978859
    [Abstract] [Full Text] [Related]

  • 32. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
    Collard RL, Harya NS, Monzon FA, Maier CE, O'Keefe DS.
    Prostate; 2006 May 15; 66(7):687-95. PubMed ID: 16425203
    [Abstract] [Full Text] [Related]

  • 33. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects.
    Hoque MO, Topaloglu O, Begum S, Henrique R, Rosenbaum E, Van Criekinge W, Westra WH, Sidransky D.
    J Clin Oncol; 2005 Sep 20; 23(27):6569-75. PubMed ID: 16170165
    [Abstract] [Full Text] [Related]

  • 34. Distinct regions of allelic loss on 13q in prostate cancer.
    Cooney KA, Wetzel JC, Merajver SD, Macoska JA, Singleton TP, Wojno KJ.
    Cancer Res; 1996 Mar 01; 56(5):1142-5. PubMed ID: 8640774
    [Abstract] [Full Text] [Related]

  • 35. Frequent hypermethylation of the RASSF1A gene in prostate cancer.
    Liu L, Yoon JH, Dammann R, Pfeifer GP.
    Oncogene; 2002 Oct 03; 21(44):6835-40. PubMed ID: 12360410
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. The MXI1 tumor suppressor gene is not mutated in primary prostate cancer.
    Kuczyk MA, Serth J, Bokemeyer C, Schwede J, Herrmann R, Machtens S, Grünewald V, Höfner K, Jonas U.
    Oncol Rep; 1998 Oct 03; 5(1):213-6. PubMed ID: 9458379
    [Abstract] [Full Text] [Related]

  • 38. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate.
    Tamboli P, Amin MB, Xu HJ, Linden MD.
    Mod Pathol; 1998 Mar 03; 11(3):247-52. PubMed ID: 9521470
    [Abstract] [Full Text] [Related]

  • 39. Cadherin switching in human prostate cancer progression.
    Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, Schalken JA.
    Cancer Res; 2000 Jul 01; 60(13):3650-4. PubMed ID: 10910081
    [Abstract] [Full Text] [Related]

  • 40. Alterations of the retinoblastoma gene in human prostate adenocarcinoma.
    Tricoli JV, Gumerlock PH, Yao JL, Chi SG, D'Souza SA, Nestok BR, deVere White RW.
    Genes Chromosomes Cancer; 1996 Feb 01; 15(2):108-14. PubMed ID: 8834174
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.